Polypeptide With Localisation/Targeting Motif TRIZ Cases

A membrane-binding, endosome-escaping editing complex inserts CAR at the TRAC locus to avoid random integration, off-target edits, and T cell loss.

Reducing Mdh activity and boosting Tat export helps coryneform bacteria secrete more heterologous protein and simplify purification.

Dual-antigen CARs target CD19 and CD22 to improve tumor killing and T-cell persistence while limiting antigen-escape relapse in B-cell cancers.

Cyclic peptides with arginine and hydrophobic aromatic residues improve endosomal escape and cytosolic delivery of intracellular cargo.

Engineered spike polypeptides remove RBD and hypervariable epitopes to focus immunity on conserved stalk regions for broader coronavirus protection.

CD84-binding CAR-T cells target blood cancer cells to improve cytotoxicity while avoiding the broad side effects of chemotherapy and radiotherapy.

Light-activated transcription factors balance protein subunit expression in biotherapeutic production, reducing by-products and improving quality.

High-affinity canine anti-CD20 antibodies and CAR fragments improve B-cell lymphoma targeting despite a hostile tumor microenvironment.

A single anti-DNP CAR pairs with DNP-conjugated tumor lipids to broaden cancer targeting without building separate antigen-specific CARs.

Synthetic TIR tuning aligns translation initiation with host ribosomes to avoid signal peptide screening and raise recombinant protein yield.

Recombinant TCRs target shared CCND1 epitopes across common HLA class II alleles while suppressing endogenous TCR expression for broader cancer therapy.

Engineered nucleases with altered PAM recognition and modified guide RNAs improve genome editing precision while reducing off-target effects.

Human-domain BCMA CARs reduce anti-CAR immunogenicity while improving T-cell persistence and cytotoxicity against multiple myeloma.

LILRB4-targeting CAR-T and CAR-NK cells attack monocytic leukemia while sparing normal hematopoietic stem cells.

Fibronectin-EDB targeting with synNotch helps CAR T-cells attack heterogeneous solid tumors while limiting immune escape and off-target toxicity.

Co-administered bisphosphonates and gamma-delta CAR T cells boost anti-tumor immunity against bone metastatic prostate cancer and limit bone damage.

Combining DAP-10, DAP12, 4-1BB, CD27, OX40, CD28, and ITAM domains boosts T-cell activation, killing, and cytokine secretion.

Novel CD33-binding CARs with short or intermediate spacers target CD33 variants and boost T cell expansion and lysis in AML.

Engineered CAR-DCs paired with radiotherapy improve tumor antigen recognition and help overcome immunosuppressive solid tumor microenvironments.

By converting PD-1 inhibitory binding into CD28 co-stimulation, this case boosts T cell killing while limiting systemic PD-1 blockade effects.

Dual BCMA/CD19 CAR-T cells use J-derived scFv sequences to improve myeloma cell killing, limit antigen escape, and support longer remission.

Modified Cav-1 peptide fragments improve lung delivery and inhibit epithelial apoptosis to reduce fibrosis in acute and chronic lung injury.

Cas9-RNP linearizes donor plasmids at a matched target site to improve HDR knock-in precision and CAR T manufacturing efficiency.

Fusing antigen fragments with an Sbi C3d-binding region boosts immunogenicity, raising antibody titers and measurable T cell responses.

C3HC4 zinc-finger degrader agents pair target-binding ligands with degradation peptides to improve selective protein knockdown, including nuclear targets.

Targeted PD-L1 sequence changes improve PD-1 and CD80 binding selectivity and immune response modulation for cancer and immunological therapy.

Bacterial DyP peroxidases target RPE cells to break down A2E while avoiding the glycosylation and scale-up limits of traditional heme enzymes.

Mutated INS1 and removal of INS2-4 improve RNA export, speeding lentiviral production while raising heterologous gene expression.

Placental MAIT cells engineered with CARs improve effector activity and in-host survival, supporting broader cell therapy use.

By coupling Tim4 phosphatidylserine binding with TLR2 signaling, engineered T cells gain stronger cytotoxicity and antigen presentation with less exhaustion.

Specific CDR3-engineered TCRs guide stem cells toward NKT differentiation while improving cell proliferation, killing activity, and cancer therapy efficacy.

A single IL-15 fusion scaffold combines IL-7 and IL-21 activity to boost immune-cell activation while reducing non-specific immune effects.

Sequence changes in the Alb-23 albumin-binding Nanobody improve expression, thermal stability, and half-life extension for therapeutic moieties.

A C-terminal NLS fused to Pa01-like serine integrase enables precise integration of DNA cargo up to 100 kb with minimal off-target events.

Immunocapture, trypsin digestion, and LC-MS/MS enable precise frataxin fusion protein measurement in tissues for FXN therapy dosing.

Whole exome sequencing, filtering, and minigene assays identify more immunogenic neoantigens for TCR-engineered cancer therapy.

Catecholamine inhibitors such as metyrosine and prazosin disrupt the inflammatory amplification loop to prevent CRS during immunotherapy.

Transient VLP delivery of CRISPR-Cas effectors with separate lentiviral cargo improves targeting while limiting prolonged expression and off-target edits.

Antigen-dependent CD33 CAR-T cells target AML blasts and leukemic stem cells, reducing leukemic burden and improving survival.

Targeted HBV DNA binding, methylation, and transcriptional repression sharply reduce viral episomes, replication, and protein expression.

By fusing ApoM to IgG Fc, this case improves plasma stability and S1P receptor activation to restore endothelial function in vascular disorders.

Bispecific anti-LILRB4 antibodies bind LILRB4 and CD3 to block immune suppression, recruit T cells, and reduce AML tumor burden.

Engineered immune cells use CD33-specific CAR domains to kill AML cells, including resistant cells, while avoiding intensive chemotherapy.

Targeted PD-1 extracellular mutations and Fc fusion improve PD-L1 binding to boost antitumor T-cell response with lower hepatotoxicity.

Engineered bioorthogonal TCR interfaces use amino acid substitutions to improve chain pairing stability and specificity while limiting cross-reactivity.

Co-expressing IL-7 and CCL19 in mesothelin-targeting CAR-T cells improves proliferation, survival, and tumor-site T-cell accumulation.

A CX3CL1 intracellular peptide with tetanus tagging improves neuronal uptake and activates insulin/IGF-1 signaling for neuroprotection.

Nanobody-based GCC CAR-T cells improve solid tumor antigen recognition and T-cell activation, boosting cytokine release and cytotoxicity.

Distinct receptor chains use transmembrane electrostatic pairing to trigger T cell signaling and regulator release with tighter CAR-T control.

Engineered immune cells bind suppressive signals such as TGF-β and convert them into activating cues to boost anti-tumor response.